Dr Göran Ando
Major Career Roles:
- Formerly Chair of Novo Nordisk A/S and Tessa Therapeutics
- Chair of Nouscom
- Chair of Eyepoint Pharmaceuticals Inc.
- Chair of Nanexa AB
- Advisor to edbi Pte Ltd, Singapore
Other Career Highlights:
- Former Chair of Symphogen A/S
- Former Board Member of Selecta Biosciences Inc
Göran has a multi-industry knowledge in healthcare, medicine, pharmaceuticals, biotechnology, and private equity. This has been acquired by over 30 years of international senior leadership experience as Chair and CEO. All this has allowed him to gain a vast wealth of experience and knowledge.
Dr Göran Ando MD was formerly Chair of Novo Nordisk A/S overseeing it´s transformational growth. He is Chair of Nouscom, Eyepoint Pharmaceuticals Inc. and Nanexa AB. In addition, Göran serves as an Advisor to edbi Pte Ltd, Singapore.
Göran is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. From 1989 to 1995, he was Medical Director, moving to Deputy R&D Director and then R&D Director of Glaxo Group Ltd. He was also a member of the Glaxo Group Executive Committee.
From 1995 to 2003 he was part of Pharmacia Corp, now Pfizer US, where he was Executive Vice President and President of R&D with additional responsibilities for manufacturing, IT, business development and mergers and acquisitions.
Göran was previously CEO of Celltech Group plc UK.